PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
详细信息 查看全文
- 作者：Jun Wang ; Ruirong Yuan ; Wenru Song ; Jingwei Sun…
- 关键词：B7 ; H1 ; PD ; L1 ; PD ; 1 ; CTLA ; 4 ; CD28 ; immune checkpoint ; immunotherapy ; immuno ; oncology ; T cells ; tumor ; site immune modulation therapy
- 刊名：Journal of Hematology & Oncology
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：10
- 期：1
- 全文大小：1158KB
- 刊物主题：Oncology; Hematology; Cancer Research;
- 出版者：BioMed Central
- ISSN：1756-8722
- 卷排序：10
文摘
The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON’s 2015 annual meeting. This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents.